Cidara Therapeutics to Participate in the World Antiviral Congress 2022
Nov 23rd, 2022 8:00 EST
SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.
The panel will discuss pandemic preparedness and therapeutic approaches, including predictions on the next viral threat, development of broad-spectrum drugs and platforms to engineer novel therapeutics.
Title: Therapeutic approaches to pandemic preparednessLocation: Loews Coronado Bay Resort, San Diego, CA, Congress Room 4Session Date/Time: December 1, 2022, at 8:20 – 9:30 a.m. PST
To register and view the full congress schedule, visit the World Antiviral Congress’ website here.
About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to DFCs targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578[email protected]
MEDIA CONTACT:Patrick BurseyLifeSci Communications(203) 430-9545[email protected]